Jpmorgan Chase & CO Roivant Sciences Ltd. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 768,489 shares of ROIV stock, worth $8.46 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
768,489
Previous 822,582
6.58%
Holding current value
$8.46 Million
Previous $9.49 Million
4.22%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ROIV
# of Institutions
324Shares Held
505MCall Options Held
573KPut Options Held
739K-
Qvt Financial LP New York, NY65.8MShares$724 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$683 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$526 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$485 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$389 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.76B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...